Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P37287

UPID:
PIGA_HUMAN

ALTERNATIVE NAMES:
GlcNAc-PI synthesis protein; Phosphatidylinositol-glycan biosynthesis class A protein

ALTERNATIVE UPACC:
P37287; B4E0V2; Q16025; Q16250

BACKGROUND:
The enzyme Phosphatidylinositol N-acetylglucosaminyltransferase subunit A, known for its role in GPI anchor biosynthesis, is essential for protein localization and function. Alternative names include Phosphatidylinositol-glycan biosynthesis class A protein.

THERAPEUTIC SIGNIFICANCE:
Given its association with critical disorders like Paroxysmal nocturnal hemoglobinuria 1 and neurodevelopmental disorders, targeting this protein could offer therapeutic avenues. Its role in disease mechanisms underscores the potential for drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.